Phase i and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 5, 2011, Pages 1101-1109

  Ueda, Yutaka ^a,c   Shimoyama, Tatsu ^a,d   Murakami, Haruyasu ^a,e   Yamamoto, Noboru ^a   Yamada, Yasuhide ^a   Arioka, Hitoshi ^b   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b YOKOHAMA ROSAI HOSPITAL   (Japan)

^c KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Pharmacokinetic; Phase I; Receptor tyrosine kinase inhibitor; Solid tumors

Indexed keywords

DIGOXIN; ORANTINIB; PROTEIN TYROSINE KINASE INHIBITOR; VERAPAMIL;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FACE EDEMA; FATIGUE; FECES; FEMALE; HEART ATRIUM FIBRILLATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPOALBUMINEMIA; JAPANESE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAL; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SOLID TUMOR; THORAX PAIN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; URINE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; POSTPRANDIAL PERIOD; PROPIONIC ACIDS; PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 79955566755     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1404-z     Document Type: Article

References (32)

1. M Toi S Hoshina T Takayanagi T Tominaga 1994 Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary beast cancer Jpn J Cancer Res 85 1045 1049 7525523 1:CAS:528:DyaK2MXltFSls7c%3D (Pubitemid 24325027)
2. K Maeda YS Chung Y Ogawa S Takatsuka SM Kang M Ogawa T Sawada M Sowa 1996 Prognostic value of vascular endothelial growth factor expression in gastric carcinoma Cancer 77 858 863 8608475 10.1002/(SICI)1097-0142(19960301)77: 5<858::AID-CNCR8>3.0.CO;2-A 1:STN:280:DyaK287osFelsA%3D%3D (Pubitemid 26061277)
3. Y Takahashi Y Kitadai CD Bucana KR Cleary LM Ellis 1995 Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer Cancer Res 55 3964 3968 7664263 1:CAS:528:DyaK2MXotV2msLg%3D
4. A Giatromanolaki MI Koukourakis S Kakolyris H Turley K O'Byrne PA Scott F Pezzella V Georgoulias AL Harris KC Gatter 1998 Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer Clin Cancer Res 4 3017 3024 9865915 1:STN:280:DyaK1M%2FotFGisQ%3D%3D (Pubitemid 29001476)
5. KJ Kim B Li K Houck J Winer N Ferrara 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo Nature 362 841 844 7683111 10.1038/362841a0 1:CAS:528:DyaK3sXktVKju7s%3D (Pubitemid 23132159)
6. DD Hu-Lowe HY Zou ML Grazzini ME Hallin GR Wickman K Amundson JH Chen DA Rewolinski S Yamazaki EY Wu MA McTigue BW Murray RS Kania P O'Connor DR Shalinsky SL Bender 2008 Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 7272 7283 19010843 10.1158/1078-0432.CCR-08-0652 1:CAS:528:DC%2BD1cXhtlylur7I
7. A Bikfalvi S Klein G Pintucci DB Rifkin 1997 Biological roles of fibroblast growth factor-2 Endocr Rev 18 26 45 9034785 10.1210/er.18.1.26 1:CAS:528:DyaK2sXhsFCiu7g%3D (Pubitemid 27076454)
8. F Yamaguchi H Saya JM Bruner RS Morrison 1994 Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas Proc Natl Acad Sci USA 91 484 488 8290551 10.1073/pnas.91.2.484 1:CAS:528:DyaK2cXhtlWjtb0%3D (Pubitemid 24041426)
9. G Seghezzi S Patel CJ Ren A Gualandris G Pintucci ES Robbins RL Shapiro AC Galloway DB Rifkin P Mignatti 1998 Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis J Cell Biol 141 1659 1673 9647657 10.1083/jcb.141.7.1659 1:CAS:528: DyaK1cXksFWqu7s%3D (Pubitemid 28309179)
10. KH Plate G Breier CL Farrell W Risau 1992 Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas Lab Invest 67 529 534 1434531 1:STN:280:DyaK3s%2FmtV2jsg%3D%3D
11. G Lindmark C Sundberg B Glimelius L Pahlman K Rubin B Gerdin 1993 Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer Lab Invest 69 682 689 8264231 1:STN:280:DyaK2c%2FovVSltg%3D%3D (Pubitemid 24026849)
12. S Rosenkranz A Kazlauskas 1999 Evidence for distinct signaling properties and biological responses induced by the PDGF receptor a and b subtypes Growth Factors 16 3 201 216 10372961 10.3109/08977199909002130 1:STN:280: DyaK1MzgtVWktA%3D%3D (Pubitemid 129725725)
13. N Sato JG Beitz J Kato M Yamamoto JW Clark P Calabresi A Raymond AR Frackelton Jr 1993 Platelet-derived growth factor indirectly stimulates angiogenesis in vitro Am J Pathol 142 1119 1130 7682762 1:CAS:528: DyaK3sXks1eqsrg%3D (Pubitemid 24060588)
14. S Ariad L Seymour WR Bezwoda 1991 Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression Breast Cancer Res Treat 20 11 17 1667486 10.1007/BF01833352 1:STN:280:DyaK383ls12gtQ%3D%3D
15. K Anan T Morisaki M Katano A Ikubo H Kitsuki A Uchiyama S Kuroki M Tanaka M Torisu 1996 Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer Surgery 119 333 339 8619189 10.1016/S0039-6060(96)80120-6 1:STN:280: DyaK283gt1Gmtg%3D%3D (Pubitemid 26082669)
16. AD Laird P Vajkoczy LK Shawver A Thurnher C Liang M Mohammadi J Schlessinger A Ullrich SR Hubbard RA Blake TA Fong LM Strawn L Sun C Tang R Hawtin F Tang N Shenoy KP Hirth G McMahon JM Cherrington 2000 SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors Cancer Res 60 4152 4160 10945623 1:CAS:528:DC%2BD3cXlvFOkt7s%3D (Pubitemid 30636598)
17. RM Shaheen DW Davis W Liu BK Zebrowski MR Wilson CD Bucana DJ McConkey G McMahon LM Ellis 1999 Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis Cancer Res 59 5412 5416 10554007 1:CAS:528:DyaK1MXnt1Gjtbg%3D (Pubitemid 29526446)
18. Japan Clinical Oncology Group 1999 National cancer institute-common toxicity criteria version 2.0, Japanese translations first version Jpn J Cancer Chemother 26 1084 1144
19. Japan Society Cancer Therapy 1993 Criteria for the evaluation of the clinical effects of solid cancer chemotherapy J Japn Soc Cancer Ther 28 101 130
20. S Yano RS Herbst H Shinohara B Knighton CD Bucana JJ Killion J Wood IJ Fidler 2000 Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation Clin Cancer Res 6 957 965 10741721 1:CAS:528:DC%2BD3cXisVaqurw%3D (Pubitemid 30159354)
21. BK Zebrowski S Yano W Liu RM Shaheen DJ Hicklin JB Putnam Jr LM Ellis 1999 Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions Clin Cancer Res 5 3364 3368 10589746 1:CAS:528:DyaK1MXotV2gs7c%3D
22. BJ Druker M Talpaz DJ Resta B Peng E Buchdunger JM Ford NB Lydon H Kantarjian R Capdeville S Ohno-Jones CL Sawyers 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037 11287972 10.1056/NEJM200104053441401 1:CAS:528:DC%2BD3MXivFGnu70%3D (Pubitemid 32267972)
23. BJ Druker CL Sawyers H Kantarjian DJ Resta SF Reese JM Ford R Capdeville M Talpaz 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 1038 1042 11287973 10.1056/NEJM200104053441402 1:CAS:528:DC%2BD3MXivFGnu7o%3D (Pubitemid 32267973)
24. AT van Oosterom I Judson J Verweij S Stroobants E Donato di Paola S Dimitrijevic M Martens A Webb R Sciot M Van Glabbeke S Silberman OS Nielsen, et al. 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 1421 1423 11705489 10.1016/S0140-6736(01)06535-7 (Pubitemid 33055745)
25. A Safi M Sadmi N Martinet O Menard P Vaillant H Gallati M Hosang Y Martinet 1992 Presence of elevated levels of platelet-derived growth factor (PDGF) in lung adenocarcinoma pleural effusions Chest 102 204 207 1320564 10.1378/chest.102.1.204 1:STN:280:DyaK38zitl2msg%3D%3D
26. MS Gordon K Margolin M Talpaz GW Sledge Jr E Holmgren R Benjamin S Stalter S Shak D Adelman 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 843 850 11157038 1:CAS:528:DC%2BD3MXhtlGrt7k%3D (Pubitemid 32119100)
27. S Faivre C Delbaldo K Vera C Robert S Lozahic N Lassau C Bello S Deprimo N Brega G Massimini JP Armand P Scigalla E Raymond 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multi target tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25 35 16314617 10.1200/JCO.2005.02.2194 1:CAS:528:DC%2BD28Xot1ChtQ%3D%3D (Pubitemid 46630490)
28. JW Clark JP Eder D Ryan C Lathia HJ Lenz 2005 Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors Clin Cancer Res 11 5472 5480 16061863 10.1158/1078-0432.CCR-04-2658 1:CAS:528:DC%2BD2MXmvFSmtbY%3D (Pubitemid 41060823)
29. BC Kuenen G Giaccone R Ruijter A Kok C Schalkwijk K Hoekman HM Pinedo 2005 Dose-finding study of the multi targeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies Clin Cancer Res 11 6240 6246 16144927 10.1158/1078-0432.CCR-04-2466 1:CAS:528:DC%2BD2MXpslansL8%3D (Pubitemid 41262954)
30. R Kitamura Y Yamamoto S Nagayama M Otagiri 2007 Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H- indol-3-ylidene)methyl]-2, 4-dimethyl-1H-pyrrole-3-propanoic acid) during oral administration twice a day to rats Drug Metab Dispos 35 1611 1616 17567729 10.1124/dmd.106.014068 1:CAS:528:DC%2BD2sXpslKqs70%3D (Pubitemid 47296055)
31. R Kitamura H Asanoma S Nagayama M Otagiri 2008 Identification of human liver cytochrome P450 isoforms involved in autoinduction of the anti-angiogenic agent TSU-68 ((Z)-5-[(1, 2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4- dimethyl-1H-pyrrole-3-propanoic acid) Drug Metab Dispos 36 1003 1009 18322074 10.1124/dmd.107.019877 1:CAS:528:DC%2BD1cXmsVOmtbw%3D (Pubitemid 351717456)
32. JR Brahmer S Kelsey P Scigalla G Hill C Bello K Elza-Brown R Donehower 2002 A phase I study of SU6668 in patients with refractory solid tumors Proc Am Soc Clin Oncol 21 335